WHO Global Advisory Committee on Vaccine Safety said in an interim statement the relationship between the vaccine and the occurrence of blood clots with low platelets is considered plausible, but is not confirmed

The COVID-19 sub-committee of WHO GACVS met on Wednesday to review the recent information from the British, EMA, and other medicines regulators

Oxford-AstraZeneca pauses COVID-19 vaccine trial in children The University of Oxford said on Tuesday it had paused a small UK trial testing the Covid-19 vaccine it developed with AstraZeneca Plc in children and teenagers, as it waits for more data on rare blood clotting issues in adults who received the shot. The trial disruption is the latest blow to the vaccine, once hailed as a milestone in the fight against the pandemic IMF raises India's growth forecast for FY22 to 12.5% Internat...

The European Medicines Agency (EMA) is currently reviewing reports of an extremely rare brain blood clot known as cerebral venous sinus thrombosis (CVST) after the AstraZeneca shots

South Africa, where a new variant now accounts for the vast bulk of cases, initially announced a pause in its rollout of a million doses of the AstraZeneca vaccine

Coronavirus vaccine update: Biopharma company Epygen Biotech with operations in Mumbai and Dubai is planning to launch an affordable COVID-19 vaccine with an aim to roll out 500 million doses within six months

Johnson & Johnson sent out a document in which it stated the \"pausing rule\" has been met and the online system used to enrol patients in the study has been closed

DCGI VG Somani in his order also asked Serum Institute to suspend any new recruitment in Phase 2 and 3 clinical trials until further notice; SII also need to increase safety monitoring of test subjects vaccinated under trials so far

Another leading candidate for coronavirus vaccine is Moderna. The company said that it is talking to multiple countries for the rollout of the COVID-19 vaccine.

AstraZeneca CEO Pascal Soriot said that the decision to resume the coronavirus vaccine trials rests with a group of independent experts who are working to understand if the volunteer's condition was coincidental or a result of the inoculation

This is a wake-up call to recognise that there are ups and downs in clinical development and that we have to be prepared, says WHO chief scientist Soumya Swaminathan

AstraZeneca on Wednesday \"voluntarily\" paused the phase 3 clinical trials after a volunteer developed an \"unexplained\" illness; in India, Serum Institute, one of the partners of University of Oxford, also decided to pause the trials following the DCGI notice

Phase 2/3 COVID-19 vaccine trials being conducted across 17 sites in India paused till further instructions from regulator; could delay vaccine development process as Serum Institute is front-runner when it comes to companies producing COVID-19 vaccines in India

British-Swedish bio-pharmaceutical firm AstraZeneca PLC, working with a team of the University of Oxford, has temporarily paused the clinical trial of its coronavirus vaccine in the UK after one of the volunteers developed an 'unexplained' illness. Serum Institute CEO, Adar Poonawalla, referred to the issue as unrelated and said that it would not impact the vaccine trials in India. Watch the video for more.Also Read: AstraZeneca pauses COVID-19 trials: In which countries are the trials taking place?

AstraZeneca vaccine trials halted: Dr. Angela Rasmussen, virologist at Columbia University said that this is exactly why Phase 3 of clinical trials are so important. She added that this might not be a big deal

The initial symptoms of Transverse myelitis include pain in the lower back or sharp, shooting sensations that radiate down the arms, legs, or around the torso

The late-stage phase 3 clinical trial of AstraZeneca's COVID-19 vaccine is being conducted at various sites, including the United Kingdom, where the adverse event was reported

\"AstraZeneca has paused the trials due to some unrelated issue with a patient in the UK, and we'll have to wait for AstraZeneca to explain what happened but this is not vaccine-related,\" says Poonawalla

AstraZeneca said in a statement that its COVID-19 vaccine candidate's trials have been halted, not stopped, as it is going to conduct a review of safety data by an independent committee